High materiality9/10
Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why
Why it may matterVerify against the original reporting
The announcement of futility signals poor prospects for REL-1017, similar to past failures in biotech.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Reliance II Phase 3 study deemed futile for REL-1017 treatment efficacy. No new safety issues were reported despite disappointing trial results. Relmada plans to analyze full data for future REL-1017 program direction. The company's focus will remain on advancing the Phase 1 REL-P11 study. RLMD stock experienced a significant decline of 75.4% post-announcement.
- Reliance II Phase 3 study deemed futile for REL-1017 treatment efficacy.
- No new safety issues were reported despite disappointing trial results.
- Relmada plans to analyze full data for future REL-1017 program direction.
- The company's focus will remain on advancing the Phase 1 REL-P11 study.
- RLMD stock experienced a significant decline of 75.4% post-announcement.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.